UK and US Stem Cell Banks team up to share expertise
Plan to drive forward stem cell research
The UK and UMASS Stem Cell Banks have signed a Memorandum of Understanding (MOU) that will outline plans for cooperation in a variety of stem cell areas including the delivery of stem cell lines for clinical use.
The agreement outlines plans for the two stem cell banks to work together to ensure that best practice and high standards in stem cell banking are employed at both sites. They will also develop international training events for scientists involved in stem cell research.
Stem cells are the body's 'master cells', with the potential to become many different types of tissue. It is hoped that stem cell treatments may be used in future to help people with Parkinson's disease, diabetes or multiple sclerosis by repairing and replacing diseased and damaged body tissue.
The UK Stem Cell Bank, funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, is a repository for human cell lines, derived from stem cells. It also holds new and existing adult, foetal and embryonic stem cell lines. Stem cell lines are provided only to accredited researchers to ensure the safe and ethical development of any potential stem cell therapy.
Dr Stephen Inglis, director of HPA's NIBSC said: ‘International co-operation is vital in this fast moving field and we expect that the partnership will accelerate the development of important new therapies, as well as keeping the UK at the forefront of stem cell research.’
Joseph Laning, senior director of the Human Stem Cell Bank and Registry at UMASS Medical School, added: ‘Both banks share common goals and needs. Working in concert allows us to develop strategies that will shape stem cell production, characterisation, banking and distribution in a dynamic field. Each bank brings its own unique attributes to bear in a way that will enhance our influence in the field.’
You may also like
Trending Articles
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development
PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific
The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape